---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-23-000037"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:53:13.626731+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biohaven submits NDA for troriluzole in SCA3; updates on Kv7, TYK2/JAK1, and SMA pipeline

## Summary
- Submitted NDA to FDA for troriluzole in SCA3, an ultra-rare disease affecting ~10,600 people in NA, EU, Japan.
- Phase 1 safety data for BHV-7000 (Kv7.2/3 activator) validates differentiated profile; pivotal studies in focal epilepsy and bipolar disorder planned in 2H2023.
- Initiated Phase 1 study for BHV-8000 (brain-penetrant TYK2/JAK1 inhibitor); Phase 2 in Parkinson's expected next year.
- Global Phase 3 trial of taldefgrobep alfa in SMA enrollment of ~225 patients expected to complete in 2023.
- IND for novel IgG degrader BHV-1300 on track for submission in 2023; multiple new INDs planned within next year.

## SEC filing metadata
- accession: 0001935979-23-000037
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000037/0001935979-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597923000037/bhvn-20230531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-23-000037
- JSON: https://secwatch.observer/filing/0001935979-23-000037.json
- Plain text: https://secwatch.observer/filing/0001935979-23-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.